The Food and Drug Administration (FDA) yesterday warned physicians against prescription falsification, saying that the flow and use of controlled drugs is being closely monitored.
A doctor in Greater Kaohsiung doctor was busted earlier this week for illegally selling controlled drugs, with the police finding stocks of buprenorphine, used in the treatment of opioid addiction, and Modipanol (flunitrazepam), a sleeping pill, on the premises.
The physician sold the drugs by fabricating patients’ signatures on the prescriptions, according to a local report, and was said to have been previously charged with illicitly selling FM2 (flunitrazepam 2mg) more than a decade ago, but was eventually acquitted.
The FDA responded to the report on Thursday by saying that the physician and his collaborators have run afoul of the Narcotics Hazard Prevention Act (毒品危害防制條例) and are liable for document fraud, adding that the physician’s license to prescribe controlled drugs will be revoked if he is found guilty of serious offenses.
The agency yesterday released the number of controlled drug violations from last year. Of a total of 183 investigations, 124 were in violation of the Controlled Drugs Act (管制藥品管理條例), followed by those against the Pharmaceutical Affairs Act (藥事法) and the Pharmacists Act (藥師法), the FDA said.
The most common violations were concerning incomplete records, failure to report inventory amount and inappropriate medical use, it added.
Tsay Wen-ying (蔡文瑛), section chief of controlled drugs at the FDA, said that there were cases involving physicians falsifying prescriptions that went overboard.
In one instance, a doctor was found prescribing addictive anesthetics for his “70-year-old mother’s menstrual cramps,” and another involved a doctor prescribing sleeping pills to hundreds of patients without any recorded disease, the official said.
The offenders were found guilty of document fraud and had their licenses annulled, the official said.